Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice
Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Molekuliarnaia biologiia - 54(2020), 6 vom: 26. Nov., Seite 939-954 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Katolikova, N V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cell differentiation |
|---|
| Anmerkungen: |
Date Completed 09.12.2020 Date Revised 14.12.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.31857/S0026898420060063 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318423596 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318423596 | ||
| 003 | DE-627 | ||
| 005 | 20231225165325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.31857/S0026898420060063 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318423596 | ||
| 035 | |a (NLM)33276357 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Katolikova, N V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cell Replacement Therapy in Parkinson's Disease-History of Development and Prospects for Use in Clinical Practice |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.12.2020 | ||
| 500 | |a Date Revised 14.12.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Parkinson's disease is a widespread neurodegenerative disease, which is characterized by the death of dopaminergic neurons in the substantia nigra of the midbrain. Clinically, the disease is manifested by tremor, bradykinesia, muscle rigidity, and other motor and non-motor symptoms that ultimately lead to disability. To date, there are only symptomatic treatment options for Parkinson's disease; therefore, the search for new approaches is one of the most important directions of therapy for this disease. In the 1970's the idea of using cell replacement therapy based on the local nature and specificity of damage to a particular type of neuron in Parkinson's disease originated. The selection of the source of cells, the method and place of introduction, indications for this operation, and peculiarities of patient management have been in development for a long time. The efficiency of cell replacement therapy has been confirmed by a number of studies on animal models. Clinical trials have already begun and several more are planned soon. This review describes the main prerequisites for the use of cell replacement therapy in Parkinson's disease, the stages of development of this method, and clinical trials that have started in the last few years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Parkinson's disease | |
| 650 | 4 | |a cell differentiation | |
| 650 | 4 | |a cell replacement therapy | |
| 650 | 4 | |a embryonic stem cells | |
| 650 | 4 | |a induced pluripotent stem cells | |
| 650 | 4 | |a neuronal progenitors | |
| 700 | 1 | |a Malashicheva, A B |e verfasserin |4 aut | |
| 700 | 1 | |a Gainetdinov, R R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molekuliarnaia biologiia |d 1975 |g 54(2020), 6 vom: 26. Nov., Seite 939-954 |w (DE-627)NLM000033979 |x 0026-8984 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2020 |g number:6 |g day:26 |g month:11 |g pages:939-954 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.31857/S0026898420060063 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2020 |e 6 |b 26 |c 11 |h 939-954 | ||